Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

19 Dec 2009

Ontario surpasses federal target for radiation therapy

For the past 12 months, Ontario has surpassed the federal target for radiation therapy wait times, demonstrating that the province has continued to improve access to this important cancer treatment.

19 Dec 2009

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

GOLFING icon Seve Ballesteros yesterday (Monday 14th December) joined forces with Cancer Research UK in a bid to beat brain cancer. Seve said he was 'lucky to be alive and owed it all to important research many people have carried out in the past'.

17 Dec 2009

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Cancer patients in Finland have gained access to more advanced treatments with the introduction of RapidArc® radiotherapy technology from Varian Medical Systems at the only private radiotherapy clinic in the Nordic region.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Initiation of multi-national Phase III study of Stimuvax announced

Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).

11 Dec 2009

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

10 Dec 2009

German researchers study target-oriented methods for children with brain tumor

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer tremendously from the stressful treatment which can be harmful to the developing brain.

10 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.

7 Dec 2009

Update on European commercial launch of MuGard for oral mucositis provided

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

4 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Earlier diagnosis of cancer saves 5,000 to 10,000 lives each year, says Professor Mike Richards

Earlier diagnosis of people with cancer could save between 5,000 and 10,000 lives each year, Professor Mike Richards, the National Cancer Director for England, has claimed.

3 Dec 2009

Radiotherapy News and Research

Further Reading

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Ontario surpasses federal target for radiation therapy

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

Discovery may yield new treatments for hormone-resistant prostate cancer

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Texas researchers identify new detection method for circulating tumor cells

Initiation of multi-national Phase III study of Stimuvax announced

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

German researchers study target-oriented methods for children with brain tumor

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Update on European commercial launch of MuGard for oral mucositis provided

PEG polymer may prevent GI injury during cancer radiotherapy

Earlier diagnosis of cancer saves 5,000 to 10,000 lives each year, says Professor Mike Richards

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News